Table: Anges - 9-MTH group results
Oct 28 (Reuters)-
Anges, Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Sep 30, 2019 Sep 30, 2018 Dec 31, 2019
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 323 mln 276 mln 335 mln
(+17.2 pct) (+8.2 pct) (-45.1 pct)
Operating loss 2.36 loss 2.24 loss 3.30
Recurring loss 2.39 loss 2.26 loss 3.30
Net loss 2.77 loss 2.20 loss 3.70
EPS loss 26.65 yen loss 26.12 yen loss 35.33 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001